NDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NIMBEX (cisatracurium besylate) by AbbVie is end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. First approved in 1995.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIMBEX (cisatracurium besylate) is a neuromuscular blocking agent administered by injection that antagonizes acetylcholine at the neuromuscular end-plate to produce paralysis during anesthesia and mechanical ventilation. It works by blocking neuromuscular transmission and is reversible with acetylcholinesterase inhibitors such as neostigmine. This agent is used primarily in operating rooms and intensive care settings to facilitate intubation and maintain paralysis during surgery or critical care.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling transition planning and potential team restructuring ahead.
Mechanism of Action
end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NIMBEX offers experience in a mature, specialty-care therapeutic area with established clinical protocols and a stable customer base in hospitals and surgical centers. However, career growth potential is limited due to the approaching loss of exclusivity and lack of pipeline expansion activity.
Brand ManagerField Sales Representative
Worked on NIMBEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.